Twist Bioscience Corp vs Vipshop Holdings Ltd - ADR — how do they compare? Twist Bioscience Corp trades at $158 (market cap $10.32B), while Vipshop Holdings Ltd - ADR trades at $12.71 (market cap $6.07B). The key difference: Twist Bioscience Corp is the larger of the two by market cap, and Vipshop Holdings Ltd - ADR pays a 4.86% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Twist Bioscience Corp for 27 Days and Vipshop Holdings Ltd - ADR for 49 Days on average.
| TWST | VIPS | |
|---|---|---|
Market Cap | $10.32B | $6.07B |
Volume | 5,894,998 | 3,134,219 |
Sector | Health | Consumer Cyclical |
52-Week High | $205.00 | $20.29 |
52-Week Low | $25.45 | $12.09 |
Typical Hold Time | 27 Days | 49 Days |
Enterprise Value | $10.24B | $2.90B |
Dividend Yield | — | 4.86% |
Signals from Pluang's Aura AI — not financial advice
TWST trades at $152.05, down 8.94% over 24 hours, with a bearish technical signal and negative cash flows. Revenue growth is strong, reaching $376.57 million in 2025, but profitability remains elusive with a net income margin of -31.66%. Recent news highlights a partnership with Lilly TuneLab for AI-driven drug discovery, providing a potential growth catalyst amid ongoing losses.
The outlook is mixed; analyst consensus is bullish with a $145.20 price target, but persistent losses and high valuation ratios pose significant risks. Investment opportunity hinges on the company's ability to monetize its AI collaborations and achieve profitability, while downside risks include cash burn and competitive pressures in the biotech sector.
Vipshop (VIPS) trades at $12.72, down 0.24% on the day, with a bullish overall technical signal. The stock appears undervalued with a P/E of 4.12 and P/S of 0.41, supported by strong profitability metrics including a 9.82% net income margin and 24.44% ROE. Recent Q2 2026 earnings missed expectations, with revenue of $105.92 billion in 2025 showing a slight decline, but net income remains robust at $7.24 billion. Analyst consensus is bullish with a $16.17 price target.
The outlook for VIPS is mixed; attractive valuation and strong cash flow generation offer upside potential, but recent earnings misses and a challenging consumer environment pose near-term risks. Investor sentiment is cautiously optimistic, with 53.57% of analysts rating it a buy, though growth stagnation remains a key concern.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →Vipshop Holdings Ltd is an online discount retailer for brands in China. The company offers branded products to consumers in China through flash sales on its vipshop.com, vip.com and lefeng.com websites. Flash sales represent an online retail format combining the advantages of e-commerce and discount sales through selling a finite quantity of discounted products or services online for a limited period of time. It deals in a wide range of products and services for consumers specializing in branded cosmetics, apparel, healthcare products, food and other consumer products. Its operating segment includes Vip.com and Shan Shan Outlets. The company generates maximum revenue from Vip.com segment.
Read more on VIPS →